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Background: The emergence of array comparative genomic hybridization (array CGH) as a diagnostic tool
in molecular genetics has facilitated recognition of microdeletions and microduplications as risk factors
for both generalised and focal epilepsies. Furthermore, there is evidence that some microdeletions/
duplications, such as the 15q13.3 deletion predispose to a range of neuropsychiatric disorders, including
intellectual disability (ID), autism, schizophrenia and epilepsy.
We hypothesised that array CGH would reveal relevant ﬁndings in an adult patient group with epilepsy
and complex phenotypes.
Methods: 82 patients (54 from the National Hospital for Neurology and Neurosurgery and 28 from King’s
College Hospital) with drug-resistant epilepsy and co-morbidities had array CGH. Separate clinicians
ordered array CGH and separate platforms were used at the two sites.
Results: In the two independent groups we identiﬁed copy number variants judged to be of pathogenic
signiﬁcance in 13.5% (7/52) and 20% (5/25) respectively, noting that slightly different selection criteria
were used, giving an overall yield of 15.6%. Sixty-nine variants of unknown signiﬁcance were also
identiﬁed in the group from the National Hospital for Neurology and Neurosurgery and 5 from the King’s
College Hospital patient group.
Conclusion: We conclude that array CGH be considered an important investigation in adults with
complicated epilepsy and, at least at present for selected patients, should join the diagnostic repertoire of
clinical history and examination, neuroimaging, electroencephalography and other indicated investiga-
tions in generating a more complete formulation of an individual’s epilepsy.
 2012 Elsevier Masson SAS. All rights reserved.1. Introduction
The ﬁeld of molecular genetics has evolved rapidly, with array
comparative genomic hybridization (array CGH) established as
a diagnostic tool in molecular genetics [1]. Array CGH provides
whole genome analysis capable of detecting genomic rearrange-
ments just a few kilobases in size, depending on the platform used
[2]. By comparison, conventional karyotyping has been reported as
in some cases being able to detect deletions as small as 5 Mb and
duplications as small as 2Mb [3]. In idiopathic intellectual disabilityExperimental Epilepsy, UCL
C1N 3BG, United Kingdom.
).
on SAS. All rights reserved.(ID), array CGH increases the yield by roughly an additional 10%
compared to conventional karyotyping alone [4].
The application of array CGH to investigate patients with
epilepsy has led to the recognition of recurrent pathogenic micro-
deletions, with 15q13.3, 16p13.11 and 15q11.2 microdeletions
emerging as signiﬁcant risk factors for generalised epilepsies, as
well as focal epilepsies in the case of 16p13.11 [5e7]. Furthermore,
there is evidence that some microdeletions/duplications predis-
pose to a range of neuropsychiatric disorders: for example, the
15q13.3 deletion that has been associated with intellectual
disability (ID), autism, schizophrenia and epilepsy [8].
There are limited published data on the use of array CGH in
adults with unexplained complex neuropsychiatric phenotypes.
Often adults represent a small proportion of most cohorts, with
only one study investigating a purely adult patient group with
idiopathic ID (mean age 35 years) [9]. With improved paediatric
Table 1
Characteristics of the patient group from the National Hospital for Neurology and
Neurosurgery.
Characteristic Percentage (Numbers)
Gender
Male 51.9% (27)
Female 48%(25)
Epilepsy classiﬁcation
Focal 75%(39)
Primary Generalised 3.8%(2)
Unclassiﬁed 19.2%(10)
Mixed 1.9%(1)
Facial Dysmorphism
Yes 42.3%(22)
Features deﬁned 36.3%(8)
Features not deﬁned 63.7%(14)
No 55.7%(29)
Not documented 1.9%(1)
Developmental Delay/Intellectual Disability (DD/ID)
Present 63.4%(33)
Absent 34.6%(18)
Not documented 1.9%(1)
Psychiatric Disorder
Yes 36.5%(19)
No 63.5%(33)
Co-morbidities
Yes 71.1%(37)
No 28.8%(15)
History of Febrile Seizures
Yes 11.5%(6)
No 88.5%(46)
Family History of Epilepsy/ID/DD/Psychiatric disorder
Yes 51.9%(27)
No 42.3%(22)
Unknown 5.8%(3)
Neuroimaging
Normal 32.7%(17)
Abnormal 55.8%(29)
Cerebellar atrophy 6.9%(2)
Generalised Atrophy 13.8%(4)
Hippocampal sclerosis 10.3%(3)
Dual pathologya 3.4%(1)
Congenital malformationb 37.9%(11)
Meningioma 3.4%(1)
High signal lesionsc 13.8%(4)
Ischaemic perinatal insult 3.4%(1)
Hydrocephalus 3.4%(1)
Intrinsic lesion with dysplastic features 3.4%(1)
Not done 10%(5)
Unknown 1.9%(1)
a Hippocampal sclerosis and a cortical malformation.
b Congenital malformations included agenesis of the corpus callosum, sub-
ependymal nodular heterotopia and dysembryoplastic neuroepithelial tumour.
c Four patients with high signal lesions; these were reported non-speciﬁc in two,
of ischaemic origin in one and related to previous head injuries in the last.
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have survived into adulthood [10]. These adults would not have had
access to current diagnostic tools during their paediatric follow up,
when theywere most likely to undergo genetic testing. For patients
who have previously undergone genetic testing, the limitations of
the methods used then, means that the genetic diagnosis may not
have been identiﬁed [10]. When a chromosomal abnormality has
been identiﬁed previously, the diagnosis may remain unchallenged,
evenwhen the clinical picture does not correlatewith reports in the
literature. With new, more accurate methods re-evaluation of such
cases is warranted.
With the growing evidence that sub-microscopic chromosomal
abnormalities may be causal or act as risk factors for a number of
neuropsychiatric disorders, including epilepsy, we hypothesised
that array CGH would reveal relevant ﬁndings in a group of adult
patients with epilepsy and complex phenotypes. We report results
for two independent adult groups, demonstrating the clinical
usefulness of array CGH and the important role molecular cytoge-
netics has to play in establishing a syndromic diagnosis.
2. Methods
2.1. Ethics
The work at the National Hospital of Neurology and Neurosur-
gery (NHNN) was approved by the relevant local Research Ethics
Committee. Patient consent, or assent from the family, was
obtained following appropriate counselling for those patients in
whom array CGH was performed as part of their clinical diagnostic
work up, or as part of an ongoing research project into the role of
genetics in epilepsy. Data from King’s College Hospital NHS Foun-
dation Trust (KCH) were part of an audit into the utility of this
investigation in one clinician’s clinic and not part of a research
project. Patients were appropriately counselled as part of routine
clinical practise when genetic testing was performed.
2.2. Cases
54 patients with drug-resistant epilepsy followed up at or
referred for assessment to the NHNN and 28 patients followed up at
or referred to KCH underwent array CGH.
Selection at NHNN was based on the presence of epilepsy in
combination with one or more of the following characteristics,
determined from medical records and outlined in Table 1: (1)
developmental delay/intellectual disability, as determined by
formal neuropsychometric testing or clinical assessment/contem-
porary documentation of developmental delay; (2) dysmorphism;
(3) family history of epilepsy, neuropsychiatric disorder or learning
disability, as deﬁned by the presence of at least one affected ﬁrst or
second degree relative; (4) personal history of a psychiatric
disorder; (5) other co-morbidities (including developmental
anomalies, abnormal neuroimaging, migraine). These criteria were
selected based on the evidence for a common genetic basis for
developmental and neuropsychiatric disorders[8], with array CGH
performed in cases seen over an 18 month period between 2009
and 2010. Epilepsy was classiﬁed according to the International
League Against Epilepsy (ILAE) Commission on Classiﬁcation and
Terminology, 2005e2009.
All cases that had array CGH performed at KCH, who had this
investigation recommended between September 10 2009 and
August 17 2010, were included in the audit, a period during which
the test was offered based on similar criteria to those listed for the
NHNN cohort but excluding abnormal neuroimaging or migraine.
These criteria were: a history of epilepsy of unknown aetiology
associated with any of the following a) developmental delay, b)learning disability, c) dysmorphism; d) mental health problems,
including autistic spectrum disorders, and/or e) a family history of
the same.
2.3. Array CGH platform and analysis
Array CGH analysis of NHNN patients was performed by the
North East Thames Regional Genetics Service, using the NimbleGen
12  135 K, whole genome v3.0 array chip, according to the manu-
facturer’s instructions. This platform has 135,000 oligonucleotide
Fig. 1. Flow diagram outlining the process used for identifying those variants of likely
pathological signiﬁcance, benign variants unlikely to be contributing to the clinical
phenotype and variants of unknown signiﬁcance. ECARUCA ¼ European Cytogeneti-
cists Association Register of Unbalanced Chromosome aberrations; OMIM ¼ online
Mendelian inheritance in Man; DGV ¼ database of Genomic variation; CNV ¼ copy
number variant.
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approximately 13 kb. Pooled reference DNA was obtained commer-
cially (Promega, UK and Kreatech, the Netherlands). The signal
intensity plots were analysed using CGH Fusion software (Info-
Quant, UK). The software average log-2-ratio threshold was set at
0.35, and a minimum of 3 consecutive probes was required for
a positive call by the software, giving this platform a functional
resolution of 200 kb (i.e. a 95% probability of picking up every variant
over 200 kb; smaller variants are also detected, but with a lower
probability)[2]. Whilst these settings can lead to a number of false
positive calls, they reduce the risk of ﬁltering out regions of copy
number change that may prove relevant to the case being investi-
gated. All calls were then checked manually to ensure they fulﬁlled
the criteria for copy number change. During this manual check,
a more stringent criterion was applied in order to limit the number
of false positive calls. To meet this criterion, any call made by the
software had to include at least three consecutive probes which
passed a log-2 ratio threshold of 0.4. Calls notmeeting this additional
criterionwere removed from further consideration. The data from 2/
54 cases were considered to be of too poor quality to be able to
distinguish between false positive and true calls with conﬁdence.
These were removed from further analysis.
King’s College Hospital array CGH was performed by the Guy’s
and St Thomas’ NHS Foundation Trust South East Thames Regional
Cytogenetics Laboratory as part of their clinical diagnostic service,
using an Agilent custom platform comprising approximately
44,000 probes across the genome, as previously described[11].
Signal intensity plots were analysed using Agilent’s DNA analytics
software, with a 3 probe sliding window providing a mean detec-
tion interval of 200 kb. Individual patient DNA samples were
compared with individual DNA from patients without epilepsy,
rather than against pooled commercial reference DNA as was the
case for the NHNN group.
2.4. Classifying signiﬁcance of copy number variants
We generated a ﬁlter to categorize variants into three groups:
likely pathogenic, benign and unknown signiﬁcance (see Fig. 1).
This ﬁlter is adapted from the algorithm proposed by Buysee
et al.[12], acknowledging that methods for determining the
signiﬁcance of copy number variants (CNVs) are still in evolution.
For the NHNN group, ﬁrst we identiﬁed variants that overlapped
with known deletion or duplication syndromes using the DECI-
PHER database (https://decipher.sanger.ac.uk). We consulted
Schinzel’s Catalogue of Unbalanced Chromosome Aberrations in
Man, 2nd edition, and the ECARUCA database (http://www.ecaruca.
net/), to identify those variants that overlapped with previously
described variants, comparing the reported phenotypes with those
of our patients. Genes encompassed by variants were identiﬁed
using the UCSC genome browser (http://genome.ucsc.edu; NCBI
build 36/hg18). Phenotypic correlations were made through the
publicly available databases, OMIM and the published literature. By
ﬁnding overlapping CNVs in patients with similar phenotypes to
those already reported, we identiﬁed variants of likely pathogenic
signiﬁcance.
Where no correlation could be made between a CNV and
a deﬁned syndrome or disease state, we searched the Database of
Genomic Variants (DGV) (http://projects.tcag.ca/variation/) to
identify those variants reported in control populations. Complete
overlap by a minimum of two controls with the same type of
variant (i.e. gain or loss) in this database was required for the
variant to be deemed a benign CNV. Where there was overlap with
just one control in DGV, or controls with a different variant to the
one being considered, the variant was then compared to a locally
compiled track. This track is based on 300 anonymised samples,collated internally and shown, following comparison with DGV,
investigation of gene content and comparison of patient pheno-
types with those known to be associated with the genes involved,
not to include any variants of known pathological signiﬁcance. If
overlap was noted between the CNV under consideration and the
locally compiled track, the variant was assigned to the group of
benign CNVs.
All regions that did not fulﬁl any of the above criteria at the end
of the ﬁlter process were classiﬁed as variants of unknown
signiﬁcance.
Among the NHNN patients, microarray was performed in both
parents for 5 patients, FISH alone was performed for the parents of
2 other patients and in one case, the patient’s mother and twin
brother underwent FISH, but the father was not available for
testing. When parental studies were available, we identiﬁed those
variants arising de novo and those inherited from a normal or
phenotypically similar parent.
Results for the KCH cohort were reported by the Guy’s Cytoge-
netic laboratory as follows: normal (only with variants recognised
in control populations), showing CNVs of likely pathogenic signif-
icance, and showing CNVs of uncertain signiﬁcance. Established
population polymorphismswere deﬁnedwhere the DGV showed at
least three publications indicating the presence of the imbalance in
control populations. Likely pathogenic signiﬁcance was assigned to
imbalances corresponding to established microdeletion regions or
susceptibility loci, those containing genes with known function
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Inheritance studies were recommended to help assess these ﬁnd-
ings further. The KCH group included three patients related to
a case previously diagnosed in the same laboratory as having
a 15q13.3 microdeletion.
3. Results
52 NHNN patients (27male, aged 18e81 years) were included in
the ﬁnal analysis; patient characteristics are given in Table 1.
Twenty-two patients were recorded as being ‘dysmorphic’. Thirty-
three patients had ID/DD. Neuropsychometric testing was not
available in one NHNN patient, as there was no clinical indication.
Neuroimaging abnormalities were reported in 55.8%; details are
given in Table 1.
In the NHNN group, we identiﬁed seven variants of likely
pathological signiﬁcance in 52 patients, giving a yield of 13.5%.
Table 2a outlines the variants found. Two had a chromosomal
abnormality diagnosed in childhood, with no further details
available. One further case was also previously documented as
having a chromosomal abnormality, not conﬁrmed by repeat
karyotype or array CGH.
In the KCH group, there were 3 individuals with a 15q13.3
microdeletion, tested during the audit period, who were related to
another known case and have therefore been excluded from anal-
ysis. There were 25 remaining patients (17 male): four had one
pathogenic variant each, whilst one had two pathogenic variants,
giving a yield of 20% (see Table 2b).
3.1. Regions of unknown signiﬁcance
We identiﬁed 65 variants of unknown signiﬁcance in the 52
cases within the NHNN group, with an average size of 523 kb and
average gene content of 2.4 genes; in the KCH cohort, 5 variants of
unknown signiﬁcance in 25 cases were identiﬁed, with an average
size of 219 kb and average gene content of 3 genes (see
Supplementary Table). The difference in the number of CNVs of
unknown signiﬁcance between the two patient groups is most
likely due to the higher probe density of the array used to test the
NHNN group.
Determining the effect these variants may have on the clinical
phenotype is often difﬁcult [12], particularly when inheritance is
unknown, a common problem in our cohort as many parents were
unavailable for testing.
Examples of such variants include two CNVs, one gain and one
loss, involving CHRNA7. In Case 3, apart from the 3.6 Mb deletion at
9p24.3p24.2, there was a 360 kb gain involving CHRNA7. Neuro-
psychiatric abnormalities have been described in six out of 11
patients with microduplication of CHRNA7 and in family members
also found to have the same microduplication[13]. Only one case
out of the 11 described had seizures. There was no formal neuro-
psychiatric history in our patient. In another patient, a small region
of copy number loss disrupting CHRNA7 was also identiﬁed. No
regions of likely pathogenic signiﬁcance were identiﬁed in this
particular case. Deletion of CHRNA7 has been implicated in idio-
pathic generalised epilepsy (IGE) in individuals with 15q13.3
deletion syndrome [14, 15]. Work by Shinawi et al. (2009) [16]
supports the hypothesis that haploinsufﬁciency of CHRNA7 is
largely responsible for the phenotype associated with 15q13.3
deletion; however, the deletion detected in our patient is smaller
than that reported by Shinawi et al., (203 kb vs 680 kb) and there
are a number of differences in the phenotypes they describe and
that of our patient. Our patient had periventricular heterotopia and
syringomyelia, with documented complex partial and secondarily
generalised tonic clonic seizures, no intellectual disability, seizureonset recorded at age 30year and no relevant family history. We
cannot comment further on the effect the small region of copy
number loss noted may have in this case and the possible inter-
action with the congenital brain malformation.4. Discussion
In two independent groups of adults with epilepsy and co-
morbidities, we identiﬁed copy number variants judged to be of
pathogenic signiﬁcance in 13.5% (7/52) and 20% (5/25) respectively,
noting that different criteria and microarray platforms were used,
giving an overall yield of 15.6%, in keeping with the literature [1].
These patients represent the ‘lost generation’, people who, if
seen as children today, would probably have array CGH as a ﬁrst
line investigation. Our results are comparable to the average diag-
nostic yield of 10e30% in published studies of array CGH in epilepsy
[17, 18] and in idiopathic developmental delay/intellectual
disability (DD/ID) with or without associated congenital anomalies
[4], suggesting that a putative genetic cause or contribution may be
important in a signiﬁcant proportion of selected patients with
epilepsy of unknown cause.
For many genetic disorders described in children there is often
a paucity of information about the evolution of the disorders with
age[10]. Adult patients may therefore present with features not
recognised as part of an otherwise well-described syndrome, so
that a genetic diagnosis is less likely to be suspected. Furthermore,
early history may have become vague or lost. During adulthood,
patients may acquire other diseases, gain weight and, particularly
in epilepsy, acquire head or facial injuries that further obscure the
phenotype. Specialists treating adults in the many varied clinical
ﬁelds are usually not trained dysmorphologists or clinical geneti-
cists. As a consequence, there may be less awareness of, or appre-
ciation for, other co-morbidities, that may point to and be explained
by a unifying genetic diagnosis. The presence of a family history or
signiﬁcance of co-morbidities may not be appreciated if history
taking focuses only on one feature, for example epilepsy, dismissing
others that form part of a complex phenotype. For these reasons
patients may not be referred to a clinical geneticist. Limited access
to clinical geneticists and their expertise may be perceived barriers
for appropriate referrals. Establishing the diagnosis brings an end to
the ‘investigative odyssey’ and aids counselling of patients and
their families in terms of prognosis, treatment options and risks for
future generations [19e21]. Our ﬁndings also suggest that such
testing is indicated, in the right setting, evenwhen imaging reveals
a structural abnormality that might be considered the cause.
Phenotypic heterogeneity makes phenotype-genotype correla-
tions challenging or impracticable, as highlighted by deletions of
15q13.3 or 16p13.11[20]. Incomplete penetrance is often suggested
as a reason for variations in phenotype associatedwith a given CNV.
Girirajan and Eichler [22] suggest variable expressivity as being the
likely explanation for clinical heterogeneity and propose a 2-hit
model, after the ﬁnding that w25% of cases with one deletion,
studied using a custom array, also carried another large deletion or
duplication. They propose that the interaction of the two CNVs is
more likely to predispose to a severe phenotype. In Case 3
(Table 2a), for example, we identiﬁed a region of copy number
change of unknown signiﬁcance affecting the CHRNA7 gene; anMRI
brain scan also showed widespread longstanding, possibly peri-
natal, ischaemic changes. We cannot determine from available data
whether the CHRNA7 duplication or the structural changes (or both
or neither) might act as a ‘second hit(s)’. As the resolution of
genomic methods and experience in the ﬁeld grow, it is likely both
that more putatively pathogenic variants will emerge and that
fewer will be deemed of ’unknown signiﬁcance’.
Table 2a
Cases from the National Hospital for Neurology and Neurosurgery with variants deemed likely pathogenic.
Case
No.
Variant
Cytoband
Copy number
change type
Size (kb) Genesa Karyotype Epilepsyb (seizure type) Co-morbidity Inheritance
1 15q11.2q13.1 Deletion 5356.7 SPG6; NDN; SNRPN;
UBE3A; ANC; MKRN3;
MAGEL2; AK124131;
BC034815; C15orf2;
IPW; PAR1; ATP10A;
GABRA5; GABRG3.
Normal Partial, of unknown
cause (Atonic; GTCS; CPS)
short stature; spastic
quadriparesis; dysconjugate
gaze; insomnia.
unknown
2 1p36.33p36.32 Deletion 2333.6 GABRD; SKI; PEX10;
TNFRSF18; TNFRSF4;
SCNN1D; CPSF3L;
TAS1R3; DVL1; AKIP;
VWA1; ATAD3B; MRPL20;
CDC2L1; MIB2;
MMP23B; MMP23A;
GNB1; NAD; CALML6;
PLCH2; HES5; TNFRSF1;
PRDM16.
NA Unclassiﬁed (GTCS; Atonic) dysmorphic; congenital
hydrocephalus; spina
biﬁda occulta; microcephaly;
obstructive sleep apnoea.
de novo
3 9p24.3p24.2 Deletion 3644.9 DOCK8; ANKRD15; DMRT1;
VLDLR; SMARCA2; RFX3;
GLIS3; HLA-HA8; KCNV2.
NA Presumed Partial,
attributable to perinatal
insult (Undeﬁned)
microcephaly; dysmorphic
face; shortened 5th
metacarpals; family history
of intellectual disability;
extensive ischaemic brain damage.
unknown
4 15q11.1q13.1 Duplication 8369.1 POTEB; TUBGCP5; CYFIP1;
NIPA1; NIPA2; NDN;
SNRPN; UBE3A; ATP10A;
GABRB3; GABRA5; GABRG3;
OCA2; HERC2.
Chromosome 15
abnormality - No
details available
Partial, of unknown
cause (Atonic; GTCS; CPS)
ﬂoppy-baby; autism; behavioural
problems; developmental delay.
de novo
5 16p13.11 Deletion 946.8 NDE1; MYH11; ABCC6. NA Partial, attributable to
malformation of cortical
development (CPS; GTCS;
Tonic seizures)
premature requiring ventilatory
assistance; panhypopituitarism;
partial agenesis of corpus callosum,
subependymal nodular heterotopia;
valvular heart disease.
unknown
6 6q22.31q22.33 Deletion 4060 NKAIN2; STL; TPD52L1;
HEY2; NCOA7; HINT3;
C6orf17; RSPO3; PTPRK.
Normal Unclassiﬁed (GTCS; Absences;
Myoclonic jerks)
low average IQ; myopia;
lymphoedema; multinodular goitre;
macular degeneration; dysmorphism;
microcephaly; family history of epilepsy.
maternal
7 4p16.3p12 Duplication 48570 ADRA2C; DOK7; SH3BP2;
FGFR3; IDUA; PDE6B; HTT;
LBN; ADD1; MSX1; WFS1;
SLC2A9; DRD5; QDPR;
MCDR2; PMX2B; PARK5;
APBB2; CNGA1.
Chromosome
4 trisomy
Unclassiﬁed (GTCS) cataracts; kyphoscoliosis; dysmorphism;
seizures associated with recurrent
respiratory arrest.
unknown
a OMIM associated genes identiﬁed using UCSC genome browser (http://genome.ucsc.edu/).
b Epilepsy syndrome based on the revised terminology and concepts for organisation of seizures and epilepsies: Report of the ILAE Commission on Classiﬁcation and Terminology, 2005e2009 NA ¼ not applicable.
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Table 2b
Variants for patients from King’s College Hospital deemed likely pathogenic.
Case No. Array karyotype Copy number Size (kb) Genesa Inheritance
1 15q13.2q13.3 x1 1.981 Mb MIR211; TRPM1; KLF13; OTUD7A;
CHRNA7; ARHGAP11A
unknown
2 Xp22.33q28
16p11.2
mosaic x1
x1
whole chromosome
525 kb
mosaic Turner syndrome
SPN; QPRT; MAZ; C16orf53; MVP;
KCTD13; TAOK2; DOC2A; GSD12;
PPP4C; TBX6; YPEL3; MAPK3; CORO1A
maternal
3 15q11.2q13.2(19,109,
124e28,153,416)x2w4,
15q13.2q13.3(28,910,
478e30,226,235)x2w3
mosaic
x2/x3/x4
10.3 Mb BCL8; TUBGCP5; CYFIP1; NIPA2;
SPG6; MKRN3; MAGEL2; NDN;
C15orf2; SNRPN; PAR5; PWCR1;
PAR1; SNORD115; ANCR; ATP10A;
GABRB3; GABRA5; GABRG3; OCA2;
HERC2; APBA2; NDNL2; TJP1;
TRPM1; KLF13; OTUD7A; CHRNA7
unknown
4 16p13.11 x1 1.144 Mb RRN3; NDE1; MYH11; ABCC1; ABCC6 unknown
5 7q35 x0 908 kb CTNAP2 unknown
a OMIM associated genes identiﬁed using UCSC genome browser (http://genome.ucsc.edu/).
E.C. Galizia et al. / European Journal of Medical Genetics 55 (2012) 342e348 347Determining the signiﬁcance of CNVs and how they should be
reported is a challenge. The presence of CNVs within ‘disease-free’
populations is well documented [23, 24], whilst inherited variants
cannot be assumed to be benign [25]. Algorithms for determining
the signiﬁcance of CNVs have been proposed by Koolen et al. [26],
and Edelmann and Hirschhorn [19]. These methods have been
employed by most studies investigating use of array CGH in idio-
pathic ID. Typically CNVs, either inherited from a normal parent or
found in control populations are identiﬁed as ‘benign’ variants.
Such variants are deemed unlikely to contribute to the patient’s
phenotype and are removed from further consideration early on in
the algorithms. The remaining variants are then assigned to one of
the two remaining groups, likely pathogenic or variants of
unknown signiﬁcance. However such an approach could exclude
variants that may contribute to the clinical picture [12]. Buysee
et al. [12], propose an alternate decision tree, which we adapted, as
a ﬁlter for the categorization of variants into the three groups of
likely pathogenic, benign and unknown signiﬁcance (see Fig. 1).
There is a recognised need for the standardization of interpreting
and reporting CNVs. Keeping within the constraints of our ﬁlter may
have led to some variants being classiﬁed here as of unknown
signiﬁcance, whilst in a clinical laboratory setting they may be
regarded as probably benign. Whilst laboratories may adopt similar
approaches for determining the clinical signiﬁcance of a CNV, the
ﬁnal interpretation has been shown to be quite variable [27]. Publicly
available databases for control populations, as used in our ﬁlters for
both groups, aid in identifying those variants that are unlikely to
contribute to a disease state. However, even in these databases
phenotypic data for the controls are typically not available and,
furthermore, one cannot assume the individuals do not carry vari-
ants that predispose to latent, later onset (after recruitment) or
recessive disease [12, 4]. This has led to calls for the sharing of data
and development of publicly available databases for genotype and
phenotype data that would aid in establishing the role of CNVs,
particularly rare CNVs, currently classiﬁed as of unknown signiﬁ-
cance [28, 4]. Detailed gene-driven phenotyping may improve
understanding of CNVs of unknown signiﬁcance, or clarify the full
phenotype associated with a given, putatively pathogenic, CNV [21].
A number of different platforms are available for detection of
CNVs, varying in their resolution (from w1 Mb for BAC arrays to
a few kilobases for oligonucleotide and single nucleotide poly-
morphism arrays), coverage of the genome (targeted vs whole
genome coverage) and source of comparator DNA. Depending on
the array used, whole genome arrays alone may miss clinically
relevant regions [29] and balanced translocations are typically not
detected [4].Our patient groups represent a highly selected population.
Much of the work using whole genome microarray in idiopathic
DD/ID relates to selected patient cohorts, with only two small
studies investigating the use of whole genome microarray in
unselected cases [30, 31]. The yield from microarray as a ﬁrst line
test in an unselected cohort of consecutive DD/ID patients has been
inferred as being w19% [11, 32]. In epilepsy, array CGH has been
used to identify candidate regions likely to harbour epilepsy-
related genes [17], with recurrent microdeletions at 15q13.3,
16p13.11 and 15q11.2 later being shown to cumulatively account for
w3% of cases with generalised epilepsy [5e7], making them the
three most common recurrent CNVs in epilepsy. Mefford et al. [6],
and Heinzen et al. [7], also identiﬁed a number of other rare CNVs.
From a practical perspective the question arises as to which
patients would beneﬁt from array CGH, as there is little guidance
about patient selection in the adult population. Increasingly, cyto-
genetics laboratories are introducing array CGH as a ﬁrst line test in
place of karyotyping. However, there is still a need for appropriate
selection in patient groups such as ours, where the link between
isolated neurocognitive disorders and copy number variation has
not yet been clearly demonstrated. We selected patients based on
the presence of certain individual or familial co-morbidities. De
Vries et al. [33], proposed a scoring system that has been adopted
by a number of groups investigating the use of array CGH in DD/ID.
The aim of the scoring system is to identify those individuals more
likely to have a deletion/duplication, by attributing points accord-
ing to the presence of a number of features including pre-natal and
post-natal growth abnormalities, dysmorphism and family history
of intellectual disability. De Vries et al. [33], demonstrated that
those individuals with pathogenic CNVs had higher scores than
thosewithout. The inclusion of severity of intellectual disability and
the presence of abnormal neuroimaging was suggested by Engels
et al. [34], to further reﬁne the de Vries score. We were unable to
apply the proposed scoring system to the two patient groups we
describe here due to lack of detail available in the clinical notes,
particularly regarding facial and non-facial dysmorphism, pre-natal
growth abnormalities and degree of ID. This is likely to reﬂect the
situation in most adult specialist clinics. However, the evidence
would suggest that the more severe the phenotype overall, the
more likely it is that a genomic abnormality will be identiﬁed [1].
We conclude that array CGH be considered an important inves-
tigation in adults with complicated epilepsy and should join the
diagnostic repertoire of clinical history and examination, neuro-
imaging, electroencephalography and other indicated investigations.
Only further data will enable its ﬁnal position in diagnosis to be
established, and considerationwill be needed of the management of
E.C. Galizia et al. / European Journal of Medical Genetics 55 (2012) 342e348348potential ‘incidental’ ﬁndings of variants relating to other conditions,
though in some cases, any such ‘other’ conditions and epilepsy may
be part of the same genomic disease [21].
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